Intranasal Ketamine for Pain Control in Patients with Sickle Cell Disease and Vaso-occlusive Episode (VOE) in the PED

NCT04150757 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

5

Enrollment

OTHER

Sponsor class

Stopped Poor recruitment secondary to COVID

Conditions

Sickle Cell Disease
Vaso-Occlusive Pain Episode in Sickle Cell Disease
Vaso-occlusive Crisis
Ketamine
Intranasal Ketamine
Analgesia

Interventions

DRUG: Intranasal ketamine

Sponsor

Abigail Nixon